26/12/2006,10525820e.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 11:50:29 ON 15 DEC 2006
FILE 'HCAPLUS' ENTERED AT 11:50:29 ON 15 DEC 2006

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	260.56	1650.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-37.50	-114.00

=> d ed abs ibib hitstr 1-37

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Aug 2006
GI



AB Provided is a process for the preparation of N-monosubstituted β-aminoalc.
sulfonates of formula I. Compds. of formula I wherein R1 is (un)substituted C6-20 aryl or (un)substituted C4-12 heteroaryl; R2 is C1-4-alkyl or (un)substituted C6-20 aryl; R3 is selected from the group consisting of C1-18 alkyl, C6-20 cycloalkyl, C6-20 aryl and C7-20 aralkyl residues, and the process for preparing compds. of formula I are claimed. The process comprising the steps of a) reacting a Me ketone, a primary amine, formaldehyde and a sulfonic acid, at a pressure above 1.5 bar, optionally in a organic solvent, said organic solvent optionally containing water,
to afford N-monosubstituted β-amino ketone sulfonates of formula II, wherein R1, R2 and R3 are as defined above, and b) asym. hydrogenating said sulfonates in the presence of a base and a catalyst, comprising a transition metal and a diphosphine ligand, in a polar solvent, optionally in the presence of water.

ACCESSION NUMBER: 2006:866581 HCAPLUS
DOCUMENT NUMBER: 145:271387
TITLE: Process for the preparation of enantiomerically pure 1-substituted-3-amino alcohols using methyl ketones, primary amines, formaldehydes and sulfonic acids
INVENTOR(S): Brieden, Walter; Clausen, Martin; McGarrity, John; Mettler, Hanspeter; Michel, Dominique
PATENT ASSIGNEE(S): Lonza A.-G., Switz.
SOURCE: PCT Int. Appl., 38pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087166	A1	20060824	WO 2006-EP1334	20060214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1693371 A1 20060823 EP 2005-3657 20050221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

PRIORITY APPLN. INFO.: EP 2005-3657 A 20050221

OTHER SOURCE(S): CASREACT 145:271387; MARPAT 145:271387
IT 906812-53-1P 906812-54-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(product; preparation of enantiomerically pure sulfonate salts of substituted amino alcs. and amino ketones by reacting Me ketones, primary amine, formaldehyde and sulfonic acids)
RN 906812-53-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 27152-62-1
CMF C10 H13 N O



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 906812-54-2 HCAPLUS
CN 1-Propanone, 3-(ethylamino)-1-phenyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 38115-24-1
CMF C11 H15 N O

L21 ANSWER 1 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 2 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Dec 2005
AB A regioselective and highly efficient synthesis of 6-amino-substituted pyridin-2(1H)-ones is presented. In situ generated propiolic acid chloride was used for the cyclization of acyclic β-keto N,S-acetals to afford the heterocyclic core. Substitution by amines led to a flexible
access of the target compds.

ACCESSION NUMBER: 2005:1284045 HCAPLUS
DOCUMENT NUMBER: 144:150218
TITLE: Efficient synthesis of 6-amino-substituted pyridin-2(1H)-ones using in situ generated propiolic acid chloride
AUTHOR(S): Schirok, Hartmut; Alonso-Alija, Cristina; Michels, Martin
CORPORATE SOURCE: Pharma Research, Bayer HealthCare AG, Wuppertal, 42096, Germany
SOURCE: Synthesis (2005), (18), 3085-3094
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:150218
IT 56617-74-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(regioselective preparation of 6-amino-2-pyridinones via heterocyclization
of β-keto N,S-acetals with in situ generated propiolic acid chloride and substitution reaction with amines)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 3 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Nov 2005
AB The keto-enol-enethiol tautomerism in 3-oxo-3-R1-N-R2-propanethioamides under vacuum and in acetone was studied in terms of d. functional theory. It was established that the equilibrium depends on the structure of the 3-oxo-3-R1-N-R2-propanethioamides and on the nature of the solvent, but the most stable form is as a rule the keto form stabilized by an intramol. hydrogen bond.
ACCESSION NUMBER: 2005:1252888 HCAPLUS
DOCUMENT NUMBER: 145:45584
TITLE: Quantum-Chemical Investigation of Keto-enol-enethiol Tautomerism in 3-oxo-3-R1-N-R2-propanethioamides
AUTHOR(S): Il'chenko, N. N.; Britsun, V. N.; Lozinskii, M. O.
CORPORATE SOURCE: Institute of Cellular Biology and Genetic Engineering, National Academy of Sciences of Ukraine, Kiev, 03143, Ukraine
SOURCE: Theoretical and Experimental Chemistry (2005), 41(5), 284-289
CODEN: TEXCAK; ISSN: 0040-5760
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 56617-74-4 876857-90-8 876857-91-9
RL: PRP (Properties)
(DFT study on keto-enol-enethiol tautomerism in 3-oxo-3-R1-N-R2-propanethioamides)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 876857-90-8 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 876857-91-9 HCAPLUS
CN Benzenepropanethioamide, N-methyl-4-nitro-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 3 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Nov 2005
GI



I



II

AB Title compds., such as I [wherein R1 = (un)substituted (hetero)aryl, aralkyl, etc.; R2 = H or (un)substituted alkyl; R3, R4 = halo, alkoxy, nitro, etc.; R5 = (un)substituted alkyl, alkoxy, amino, etc.; m = 0-4, with limitations, and pharmaceutically acceptable salts, prodrugs or solvates thereof] were prepared as modulators of GABAA and nicotinic acetylcholine receptors. For instance, 2,2-dimethyl-1,3-dioxane-4,6-dione underwent condensation successively with 2-chlorobenzoyl chloride in the presence of DMAP, propylamine, N,N-dimethylformamide dimethylacetal and 4-(trifluoromethyl)aniline to give II. Several biol. assays were executed. Representative I showed inhibition against GABA receptor with IC50 of 0.01 - 0.20 μM in the (35S)-TBPS binding assay. Therefore, the invented compds. and their pharmaceutical comprns. are useful for the treatment of CNS disorders amenable to modulation of GABAA and nicotinic acetylcholine receptors.
ACCESSION NUMBER: 2005:1220692 HCAPLUS
DOCUMENT NUMBER: 143:477643
TITLE: Preparation of enaminones as modulators of GABAA and nicotinic acetylcholine receptors
INVENTOR(S): Hogenkamp, Derk J.; Johnstone, Timothy B. C.; Gee, Kelvin W.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108347	A2	20051117	WO 2005-US15869	20050505
WO 2005108347	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2004-569465P P 20040506

OTHER SOURCE(S): MARPAT 143:477643
IT 869555-11-3P 869555-14-6P 869555-16-8P
869555-17-9P 869555-57-7P 869555-58-8P
869555-61-3P 869555-62-4P 869555-79-3P
869555-86-2P 869555-87-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of enaminones as modulators of GABAA and nicotinic acetylcholine receptors)
RN 869555-11-3 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-α-[[(4-iodophenyl)amino]methylene]-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-14-6 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-β-oxo-α-(pyrazinylamino)- (9CI) (CA INDEX NAME)



RN 869555-16-8 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-β-oxo-α-[(4H-1,2,4-triazol-4-ylamino)methylene]- (9CI) (CA INDEX NAME)

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869555-17-9 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-α-[(3-isoxazolylamino)methylene]-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-57-7 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[[(4-chlorophenyl)amino]methylene]-N-ethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-58-8 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[[(4-ethoxyphenyl)amino]methylene]-N-ethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869555-61-3 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[[(4-iodophenyl)amino]methylene]-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-62-4 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[[(4-chlorophenyl)amino]methylene]-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-79-3 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[[(4-cyanophenyl)amino]methylene]-N-ethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-86-2 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-α-[[[1-(4-

L21 ANSWER 4 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
fluorophenyl)ethyl]amino]methylene]-β-oxo- (9CI) (CA INDEX NAME)



RN 869555-87-3 HCAPLUS
CN Benzenepropanamide, 2-chloro-N-ethyl-β-oxo-α-[[(1-phenylethyl)amino]methylene]- (9CI) (CA INDEX NAME)



IT 869555-09-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of enaminones as modulators of GABAA and nicotinic acetylcholine receptors)
RN 869555-09-9 HCAPLUS
CN Benzenepropanamide, 2-chloro-α-[(dimethylamino)methylene]-N-ethyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 5 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Nov 2005
AB Ru-SYNPHOS and Ru-DIFLUORPHOS catalysts were efficiently used for the synthesis of a wide variety of chiral β-hydroxy amides via asym. hydrogenation of the corresponding β-keto amides.

ACCESSION NUMBER: 2005:1174285 HCAPLUS
DOCUMENT NUMBER: 144:69604
TITLE: Ru-SYNPHOS and Ru-DIFLUORPHOS: Highly efficient catalysts for practical preparation of β-hydroxy amides
AUTHOR(S): Touati, Ridha; Gmiza, Thouraya; Jeulin, Severine; Deport, Coralie; Ratovelomanana-Vidal, Virginie; Ben Hassine, Bechir; Genet, Jean-Pierre
CORPORATE SOURCE: Laboratoire de Synthese Organique Asymetrique et Catalyse Homogene, Faculte des Sciences de Monastir, Monastir, 5019, Tunisia
SOURCE: Synlett (2005), (16), 2478-2482
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:69604

IT 197852-01-0
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(hydrogenation kinetics; preparation of β-hydroxy amides by asym. hydrogenation of β-keto amides using ruthenium Synphos and Difluorphos catalysts)
RN 197852-01-0 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



IT 123987-17-7 871578-97-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of β-hydroxy amides by asym. hydrogenation of β-keto amides using ruthenium Synphos and Difluorphos catalysts)
RN 123987-17-7 HCAPLUS
CN Benzenepropanamide, N,4-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 871578-97-1 HCAPLUS
CN Benzenepropanamide, 4-fluoro-N-methyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 5 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Sep 2005
AB The improved method of the synthesis of 3-oxo-3-R1-N-R2-propanthioamides is proposed based upon (i) the preparation of sodium enolates of 1,3-dicarbonyl compds. (R1COCH-COMe.Na+), (ii) their subsequent thiocarbamoylation with R2N:C:S and neutralization to afforded acetyl derivs. R1COCH(Ac)CSNHR2, and (iii) hydrolysis to afford the title compds. R1COCH2CSNHR2. The ratio of keto- and enol forms of 3-oxo-3-R1-N-R2-propanthioamides in different solvents was studied by the methods of NMR 1H spectroscopy and IR spectroscopy.
ACCESSION NUMBER: 2005:994248 HCAPLUS
DOCUMENT NUMBER: 144:253708
TITLE: Improved method for the synthesis and keto-enol tautomerism of 3-oxo-3-R1-N-R2-propanethioamides
AUTHOR(S): Britsun, V. M.; Borisevich, A. M.; Samoilenko, L. S.; Lozins'kii, M. O.
CORPORATE SOURCE: Inst. Org. Khim., NAN Ukr., Kiev, Ukraine
SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (2005), 71(7-8), 111-116
CODEN: UKZHAU; ISSN: 0041-6045
PUBLISHER: Institut Obshchei i Neorganicheskoi Khimii im. V. I. Vernadskogo NAN Ukrainy
DOCUMENT TYPE: Journal
LANGUAGE: Ukrainian
OTHER SOURCE(S): CASREACT 144:253708
IT 910296-57-0 910296-74-1 910296-87-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(improved synthesis and keto-enol tautomerism of 3-oxopropanethioamides and solvent and substituent effects thereon)
RN 910296-57-0 HCAPLUS
CN Benzenepropanethioamide, α-acetyl-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 910296-74-1 HCAPLUS
CN Benzenepropanethioamide, α-acetyl-4-methoxy-N-methyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910296-87-6 HCAPLUS
CN Benzenepropanethioamide, α-acetyl-N-methyl-4-nitro-β-oxo- (9CI) (CA INDEX NAME)



IT 56617-74-4P 876857-90-8P 876857-91-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(keto-enol tautomerism; improved synthesis and keto-enol tautomerism of 3-oxopropanethioamides and solvent and substituent effects thereon)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 876857-90-8 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 876857-91-9 HCAPLUS
CN Benzenepropanethioamide, N-methyl-4-nitro-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 6 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L21 ANSWER 7 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 06 Jul 2005
AB Polymer-supported chiral ligands were prepared based on Noyori's (1S,2S)- or (1R,2R)-N-(p-tolylsulfonyl)-1,2-diphenylethylenediamine. The combination with [RuCl2(p-cymene)]2 has been shown to exhibit high activities and enantioselectivities for heterogeneous asym. transfer hydrogenation of aromatic ketones with formic acid-triethylamine azeotrope as the hydrogen donor, whereby affording the resp. optically active alcs., the key precursors of chiral fluoxetine. The catalysts can be recovered and reused in three consecutive runs with no significant decline in enantioselectivity. The procedure avoids the plausible contamination of fluoxetine by the toxic transition metal species.
ACCESSION NUMBER: 2005:580715 HCAPLUS
DOCUMENT NUMBER: 143:248107
TITLE: Preparation of polymer-supported Ru-TsDPEN catalysts and use for enantioselective synthesis of (S)-fluoxetine
AUTHOR(S): Li, Yangzhou; Li, Zhiming; Li, Feng; Wang, Quanrui; Tao, Fanggang
CORPORATE SOURCE: Department of Chemistry, Fudan University, Shanghai, 200433, Peop. Rep. China
SOURCE: Organic & Biomolecular Chemistry (2005), 3(14), 2513-2518
CODEN: OBCRAK; ISSN: 1477-0520
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:248107
IT 197852-01-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of polymer-supported Ru-TsDPEN catalysts for enantioselective synthesis of (S)-fluoxetine)
RN 197852-01-0 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Mar 2005
AB Several β-secondary amino ketone hydrochlorides were hydrogenated with remarkably high enantioselectivities by using a rhodium complex containing P-chiral bisphospholane. These results establish a short and practical means for the synthesis of enantiopure N-monosubstituted γ-amino alcs., which are key intermediates in the synthesis of important antidepressants. For example, the bis[di(methyl)ethyl]tetra(hydro)-1,1'-bi-1H-isophosphindole-rhodium-catalyzed stereoselective hydrogenation of 3-(methylamino)-1-phenyl-1-propanone hydrochloride gave (αS)-α-[2-[(methyl)amino]ethyl]benzenemethanol, which is a synthetic precursor for (γS)-N-methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine [i.e., (S)-fluoxetine]. The synthesis of (αS)-[-[(methyl)amino]ethyl]thiophenemethanol, a key synthetic intermediate for (S)-duloxetine, was also reported.
ACCESSION NUMBER: 2005:251916 HCAPLUS
DOCUMENT NUMBER: 142:481782
TITLE: Practical synthesis of enantiopure γ-amino alcohols by rhodium-catalyzed asymmetric hydrogenation of β-secondary-amino ketones
AUTHOR(S): Liu, Duan; Gao, Wenzhong; Wang, Chunjiang; Zhang, Xumu
CORPORATE SOURCE: Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA
SOURCE: Angewandte Chemie, International Edition (2005), 44(11), 1687-1689
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:481782
IT 2538-50-3P 24206-62-0P 851878-34-7P 851878-36-9P 851878-38-1P 851878-40-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral [(methyl)amino]ethyl]arenemethanol by bis[di(methyl)ethyl]tetra(hydro)-1,1'-bi-1H-isophosphindole-rhodium-catalyzed stereoselective hydrogenation using (aryl)[(methyl)amino]propanone hydrochloride as synthetic intermediate)
RN 2538-50-3 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 24206-62-0 HCAPLUS
CN 1-Propanone, 1-(4-methoxyphenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



RN 851878-34-7 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 851878-36-9 HCAPLUS
CN 1-Propanone, 1-(3-bromophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



RN 851878-38-1 HCAPLUS
CN 1-Propanone, 1-(4-bromophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 8 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 851878-40-5 HCAPLUS
CN 1-Propanone, 1-(2-methoxyphenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



L21 ANSWER 9 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Sep 2004
GI



I

AB A series of 11b-substituted 1,6,7,11b-tetrahydropyrimido[6,1-a]-isoquinoline-2,4-diones and 4-thioxo-1,3,4,6,7,11b-hexahydropyrimido[6,1-a]isoquinolin-2-ones, e.g., I, were synthesized, utilizing two alternative strategies for ring closure of tetrahydroisoquinoline intermediates obtained from N-phenethyl enaminones.

ACCESSION NUMBER: 2004:757242 HCAPLUS
DOCUMENT NUMBER: 143:26552
TITLE: Synthesis of some novel 11b-substituted pyrimido[6,1-a]isoquinoline derivatives
AUTHOR(S): Angelov, Plamen A.; Ivanov, Iliyan I.; Venkov, Atanas P.
CORPORATE SOURCE: Department of Organic Chemistry, University of Plovdiv, Plovdiv, 4000, Bulg.
SOURCE: Molecules (2004), 9(8), 694-704
CODEN: MOLEFW; ISSN: 1420-3049
URL: http://www.mdpi.org/molecules/papers/90800694.pdf
PUBLISHER: Molecular Diversity Preservation International
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:26552

IT 197852-01-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of tetrahydroisoquinolinylacetamides via heterocyclization of homoveratrylamine with β-keto amides in the preparation of pyrimidoisoquinoline derivs.)

RN 197852-01-0 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 9 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS FORMAT
RECORD. ALL CITATIONS AVAILABLE IN THE RE

L21 ANSWER 10 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Mar 2004
GI



I



II

AB The invention relates to methods for the enantioselective production of amino alcs., R1CH(OH)CH2(CH2)nNHR2 [R1 = (un)substituted, (un)saturated or aromatic carbocycle or heterocycle (optionally substituted with R3, R4); R2 = H, C1-20-alkyl; R3, R4 = H, C1-20-alkyl, C1-20-alkoxy, aryl, aryloxy, CO2R2, F, Cl, Br, OH, CN,NO2,N(R2)2, NHCOR2; n = 0 - 3], via the enantioselective hydrogenation of amino ketones, R1COCH2(CH2)nNHR2 and is characterized by hydrogenation in the presence of a non-racemic catalyst containing a chiral diphosphine ligand I [R5, R6, R7, R8 = H, C1-20-alkyl, C1-20-alkoxy, aryl, aryloxy, F, Cl, Br,N(R2)2, NHCOR2; R5R6, R6R7, R7R8 = (CH2)4, CH:CHCH:CH,etc.; R9, R10 = C6H4(R11)m, 2-furyl, cyclohexyl; R11 = H, C1-20-alkyl, C1-20-alkoxy, aryl, aryloxy, SO3Na, COR12, F, Cl, N(R12)2, NHCOR12; R12 = H, C1-20-alkyl; m = 0 - 3] or II [Q = PPh2, P(cyclohexyl)2, P[C6H3(CF3)2-3,5], P(4-methoxy-3,5-dimethylphenyl)2, P(CMe3)2; Y = OH, P(cyclohexyl)2, P(C6H3Me2-3,5)2, P(CMe3)2; Z = H, PPh2; Ph = unsubstituted Ph, C6H4Me-2, C6H4Me-3, C6H4Me-4, C6H3Me2]. Thus, (S)-N-methyl-3-hydroxy-3-(2-thienyl)propanamine was prepared with 92.8% e.e. from 3-(methylamino)-1-(2-thienyl)-1-propanone via asym. hydrogenation in MeOH/PhMe containing catalytic bis(1,5-cyclooctadiene)dirhodium(I) dichloride and (S)-(-)-2,2'-bis[di(p-tolyl)phosphine]-1,1'-binaphthyl.

ACCESSION NUMBER: 2004:203795 HCAPLUS
DOCUMENT NUMBER: 140:253262
TITLE: Method for the preparation amino alcohols via the enantioselective hydrogenation of amino ketones

L21 ANSWER 10 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INVENTOR(S): Kralik, Joachim; Fabian, Kai; Muermann, Christoph; Schweickert, Norbert
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020389	A1	20040311	WO 2003-EP8513	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2496883	AA	20040311	CA 2003-2496883	20030801
AU 2003260347	A1	20040319	AU 2003-260347	20030801
EP 1532100	A1	20050525	EP 2003-790842	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013795	A	20050712	BR 2003-13795	20030801
CN 1678562	A	20051005	CN 2003-820304	20030801
JP 2005536556	T2	20051202	JP 2004-531845	20030801
US 2005261514	A1	20051124	US 2005-525821	20050225
ZA 2005002458	A	20051010	ZA 2005-2458	20050324
PRIORITY APPLN. INFO.:			DE 2002-10240025 A	20020827
			WO 2003-EP8513 W	20030801

OTHER SOURCE(S): CASREACT 140:253262; MARPAT 140:253262

IT 27152-62-1, 3-(Methylamino)-1-phenyl-1-propanone
RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective hydrogenation of; preparation amino alcs. via the enantioselective hydrogenation of amino ketones with chiral diphosphine ligands)

RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS FORMAT
RECORD. ALL CITATIONS AVAILABLE IN THE RE

L21 ANSWER 11 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 Mar 2004
AB R1COCH2CH2NHR2 [R1 = (substituted) (unsatd.) residue, aromatic heterocyclyl;
R2 = alkyl], were prepared by reaction of R1COCH2CH2NR2CH2CH2COR1 (variables
as above) with R2NH2.
ACCESSION NUMBER: 2004:198214 HCAPLUS
DOCUMENT NUMBER: 140:235592
TITLE: Process for the preparation of monoalkylaminoethyl aryl ketones from bis(arylcarbonylethyl)alkylamines.
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: Ger. Offen., 7 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10240026	A1	20040311	DE 2002-10240026	20020827
CA 2497028	AA	20040311	CA 2003-2497028	20030801
WO 2004020391	A1	20040311	WO 2003-EP8514	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003260348	A1	20040319	AU 2003-260348	20030801
EP 1532101	A1	20050525	EP 2003-790843	20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013796	A	20050927	BR 2003-13796	20030801
CN 1678564	A	20051005	CN 2003-820305	20030801
JP 2005536557	T2	20051202	JP 2004-531846	20030801
US 2006122405	A1	20060608	US 2005-525820	20050225
ZA 2005002457	A	20051025	ZA 2005-2457	20050324

PRIORITY APPLN. INFO.: DE 2002-10240026 A 20020827
WO 2003-EP8514 W 20030801

OTHER SOURCE(S): CASREACT 140:235592; MARPAT 140:235592
IT 27152-62-1P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of monoalkylaminoethyl aryl ketones from bis(arylcarbonylethyl)alkylamines)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)

L21 ANSWER 11 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L21 ANSWER 12 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 22 Jan 2004
AB The first general protocol for the anti-selective reduction of α-alkyl-β-keto amides is described. This simple and efficient methodol. based on an open-chain Felkin-Anh model pathway, allows the isolation of N-mono- and non-substituted anti-α-substituted β-hydroxy amides in good yields and with high diastereoselectivity.
ACCESSION NUMBER: 2004:55261 HCAPLUS
DOCUMENT NUMBER: 140:217079
TITLE: Highly stereoselective reduction of β-keto amides. The first general and efficient approach to N-mono- and non-substituted anti-α-alkyl β-hydroxy amides
AUTHOR(S): Bartoli, Giuseppe; Bosco, Marcella; Marcantoni, Enrico; Melchiorre, Paolo; Rinaldi, Samuele; Sambri, Letizia
CORPORATE SOURCE: Dipartimento di Chimica Organica "A. Mangini", Universita di Bologna, Bologna, 40136, Italy
SOURCE: Synlett (2004), (1), 73-76
CODEN: SYNLES; ISSN: 0936-5214
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:217079
IT 24956-49-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereoselective reduction of β-keto amides to N-mono- and non-subetituted anti-α-alkyl β-hydroxy amides)
RN 24956-49-8 HCAPLUS
CN Benzenepropanamide, N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 13 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Jan 2004
AB The invention relates to a process for the synthesis of N-monosubstituted β-amino alcs. of formula HOCH(R1)CH2CH2NHR2 and/or an addition salt of a proton acid (wherein R1 and R2 independently represent alkyl, cycloalkyl, aryl or aralkyl, each being optionally further substituted with alkyl, alkoxy and/or halogen) via direct preparation of N-monosubstituted β-amino
ketones of R1COCH2CH2NHR2 and its addition salts of proton acids (wherein R1
and R2 are as defined above). Thus, 2-acetylthiophene 25.5, methylamine hydrochloride 14.9, paraformaldehyde 8.2, concentrated HCl 1.0 g, 100 mL ethanol
were heated in an autoclave at 110° and a total pressure of 2-2.5 bar for 9 h, followed by removing 50 mL ethanol in vacuo and addition of 200
mL Et acetate under vigorous stirring, and filtration to give 71% 3-(methylamino)-1-(thiophen-2-yl)propan-1-one hydrochloride (I). To a mixture of 10.3 g I and 35 mL ethanol at 4° sodium hydroxide (4.0 g of a 50% aqueous solution) was added in about 5 min and afterwards, 0.95 g neat
sodium borohydride in several portions in about 30 min. The resulting suspension was stirred for 4 h at the same temperature, treated dropwise with
10.0 mL acetone in 5 min, stirred for 10 addnl. minutes, treated with 20 mL H2O, concentrated about 5 times under vacuum, and extracted with tert-Bu Me ether
(2 x 20 mL). The collected organic phases were finally concentrated under vacuum
affording an orange oil which crystallized spontaneously after a few hours to
give 3-(methylamino)-1-(thiophen-2-yl)propan-1-ol as an orange solid (7.2 g, 84 % yield).
ACCESSION NUMBER: 2004:41430 HCAPLUS
DOCUMENT NUMBER: 140:93914
TITLE: Process for the preparation of N-monosubstituted β-amino alcohols
INVENTOR(S): Michel, Dominique
PATENT ASSIGNEE(S): Lonza A.-G., Switz.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005239	A1	20040115	WO 2003-EP7411	20030709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491472	AA	20040115	CA 2003-2491472	20030709

L21 ANSWER 13 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AU 2003250924	A1	20040123	AU 2003-250924		20030709
BR 2003012651	A	20050426	BR 2003-12651		20030709
EP 1539673	A1	20050615	EP 2003-762669		20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1665773	A	20050907	CN 2003-816223		20030709
JP 2005532383	T2	20051027	JP 2004-518758		20030709
NO 2005000079	A	20050311	NO 2005-79		20050106
US 2005256318	A1	20051117	US 2005-520362		20050418
PRIORITY APPLN. INFO.:			EP 2002-15229	A	20020709
			WO 2003-EP7411	W	20030709

OTHER SOURCE(S): CASREACT 140:93914; MARPAT 140:93914
IT 2538-50-3P, 3-(Methylamino)-1-phenylpropan-1-one hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; process for preparation of N-monosubstituted β-amino alcs. by reduction of N-monosubstituted β-amino ketones)
RN 2538-50-3 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 14 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Dec 2003
AB The title compound was prepared from β-bromopropiophenone by amination and reduction The recovery rate of the first step was 82.7%, and that of the second step was 87.0%. The purity of the product was 99.4%.
ACCESSION NUMBER: 2003:958874 HCAPLUS
DOCUMENT NUMBER: 141:90826
TITLE: Optimization of the technological conditions for synthesis of 3-(methylamino)-1-phenylpropyl alcohol
AUTHOR(S): Zhang, Zheng-guang; Li, Yu-shan
CORPORATE SOURCE: Institute of Chemistry and Life Science, Three Gorges University, Yichang, 443002, Peop. Rep. China
SOURCE: Jilin Huagong Xueyuan Xuebao (2003), 20(3), 17-18
CODEN: JHXUFO; ISSN: 1007-2853
PUBLISHER: Jilin Huagong Xueyuan Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 141:90826
IT 27152-62-1P, β-(Methylamino)propiophenone
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 15 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Nov 2003
GI



I

II



III

AB Title compds. I [X, Y = H, aryl, cyano, etc.; R1 = H, alkyl, alkenyl, etc.; R2, R3 = H, alkyl, hydroxyalkylene (sic), etc.], their diastereomers and pharmaceutically acceptable salts were prepared For example, condensation of 4-aminobenzamide, triethylorthoformate and thiazolidinone II, e.g., prepared from cyanoacetic acid Et ester in 2-steps, afforded a diastereomeric mixture of thiazolidinones III. In human polo-like kinase-1 (PLK-1) inhibition assays, 29-examples of compds. I exhibited IC50 values ranging from 100-6300 nM, e.g., the IC50 value of thiazolidinones III was 200 nM.
ACCESSION NUMBER: 2003:892761 HCAPLUS
DOCUMENT NUMBER: 139:381496
TITLE: Preparation of (4-oxo-2-thiazolidinylidene)acetonitriles and related compounds as polo-like kinase-1 (PLK-1) inhibitors
INVENTOR(S): Schwede, Wolfgang; Schulze, Volker; Eis, Knut; Buchmann, Bernd; Briem, Hans; Siemeister, Gerhard; Boemer, Ulf; Parczyk, Karsten
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093249	A1	20031113	WO 2003-EP4450	20030429

L21 ANSWER 15 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2484597	AA	20031113	CA 2003-2484597		20030429
AU 2003222845	A1	20031117	AU 2003-222845		20030429
EP 1501794	A1	20050202	EP 2003-718796		20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003009758	A	20050215	BR 2003-9758		20030429
CN 1649853	A	20050803	CN 2003-810042		20030429
JP 2005538048	T2	20051215	JP 2004-501388		20030429
NO 2004005281	A	20050201	NO 2004-5281		20041202
US 2006079503	A1	20060413	US 2005-513368		20050810
PRIORITY APPLN. INFO.:			DE 2002-10221104	A	20020503
			WO 2003-EP4450	W	20030429

OTHER SOURCE(S): MARPAT 139:381496
IT 623558-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thiazolidinones as polo-like kinase-1 (PLK-1) inhibitors)
RN 623558-84-9 HCAPLUS
CN Benzenepropanethioamide, α-cyano-N-ethyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 16 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Sep 2003
GI



AB The present invention relates to amino(monocyclic aroyl)pyridinones (shown as I; variables defined below; e.g. 5-benzoyl-1-(2-methoxyethyl)-6-[(2-methoxyethyl)amino]-2(1H)-pyridinone), processes for their preparation, and their use in medicaments, especially for the treatment of COPD and asthma. IC50 values are tabulated for inhibition of p38 map kinase by 8 examples of I, e.g. 0.202 μM for 6-amino-5-benzoyl-1-phenyl-2(1H)-pyridinone. For I: R1 = H, C1-C8-alkyl, C6-C10-aryl, heteroaryl, C3-C8-cycloalkyl or heterocyclyl, wherein C1-C8-alkyl, C6-C10-aryl, heteroaryl, heterocyclyl or C3-C8-cycloalkyl can be substituted with 0 to 3 substituents; R2 = H, amino, mono- or diC1-C6-alkylamino, C3-C8-cycloalkylamino, C6-C10-arylamino, C1-C8-alkyl, C6-C10-aryl, heteroaryl, C3-C8-cycloalkyl or heterocyclyl, wherein mono- or diC1-C6-alkylamino, C3-C8-cycloalkylamino, C6-C10-arylamino, C1-C8-alkyl, C6-C10-aryl, heteroaryl, heterocyclyl or C3-C8-cycloalkyl can be substituted with 0 to 3 substituents. R3 = H or C1-C6-alkyl; R4 = -COR4-1, wherein R4-1 = C6-C10-aryl or heteroaryl; with the proviso that R1, R2 and R3 are not H at the same time; addnl. details are given in the claims. More than 100 example prepns. and/or characterization data of intermediates and 155 of I are included. For example, 5-benzoyl-1-(2-methoxyethyl)-6-[(2-methoxyethyl)amino]-2(1H)-pyridinone (22 %) was prepared from 3,3-bis[(2-methoxyethyl)amino]-1-phenyl-2-propen-1-one (0.61 mmol), propiolic acid (0.92 mmol) and 1-[(1H-imidazol-1-yl)carbonyl]-1H-imidazole (1.10 mmol).

ACCESSION NUMBER: 2003:737727 HCAPLUS
DOCUMENT NUMBER: 139:261170
TITLE: Preparation of amino(monocyclic aroyl)pyridinones that inhibit p38 map kinase for use as antiinflammatory agents
INVENTOR(S): Alonso-Alija, Cristina; Michels, Martin; Schirok, Hartmut; Schlemmer, Karl-Heinz; Bell, John; Fitzgerald, Mary F.; Dodd, Sara; Gill, Andrew
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

L21 ANSWER 16 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076405	A1	20030918	WO 2003-EP2154	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478936	AA	20030918	CA 2003-2478936	20030303
AU 2003223953	A1	20030922	AU 2003-223953	20030303
EP 1487794	A1	20041222	EP 2003-720315	20030303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008429	A	20050111	BR 2003-8429	20030303
CN 1653047	A	20050810	CN 2003-810486	20030303
JP 2005526068	T2	20050902	JP 2003-574626	20030303
ZA 2004007211	A	20050909	ZA 2004-7211	20040909
US 2006046999	A1	20060302	US 2005-507754	20050523

PRIORITY APPLN. INFO.:

GB 2002-6019	A	20020314
GB 2002-21951	A	20020920
GB 2002-27431	A	20021125
WO 2003-EP2154	W	20030303

OTHER SOURCE(S): MARPAT 139:261170
IT 56617-74-4, N-Methyl-3-oxo-3-phenylpropanethioamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino(monocyclic aroyl)pyridinones that inhibit p38 map kinase for use as antiinflammatory agents)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 17 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 May 2003
AB Mixts. of 3-benzoylated and 3-unsubstituted 6-hydroxypiperidine-2-thione derivs. were formed in the reaction of benzoyl(acetyl) thioacetamides with α,β-unsatd. aldehydes in refluxing ethanol in the presence of catalytic amts. of triethylamine. A mechanism for the debenzoylation was proposed. Derivs. of 6H-thiopyran were obtained when an analogous reaction was carried out in refluxing pyridine. The structures of all compds. were determined with the aid of 1D NMR (1H, 13C, 13C-DEPT-135) and 2D NMR (1H, 1H COSY, 1H, 1H NOESY, 13C, 1H COSY) spectroscopy.

ACCESSION NUMBER: 2003:406299 HCAPLUS
DOCUMENT NUMBER: 139:230588
TITLE: Reactions of β-keto thioamides with α,β-unsaturated aldehydes. Synthesis of 6-hydroxypiperidine-2-thiones and 6H-thiopyrans
AUTHOR(S): Jagodzinski, Tadeusz S.; Sosnicki, Jacek G.; Wesolowska, Aneta
CORPORATE SOURCE: Department of Organic Chemistry, Technical University of Szczecin, Szczecin, PL-71065, Pol.
SOURCE: Tetrahedron (2003), 59(23), 4183-4192
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:230588
IT 56617-74-4 56617-75-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactions of β-keto thioamides with α,β-unsatd. aldehydes)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 56617-75-5 HCAPLUS
CN Benzenepropanethioamide, N-ethyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Oct 2002
AB In the search for new active bis-β-aminoketones, a series of compds. was synthesized by aminomethylation of p-substituted 1,6-bisaryl-1,6-hexanediones and 1,8-bisaryl-1,8-octanediones with ethylamine or tert-butylamine. The 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides are stable crystalline substances, whereas many of the 1,8-bisaryl-2,7-bis(aminomethyl)-1,8-octanedione dihydrochlorides are hygroscopic. The 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides administered in a dose of 10 mg/kg exhibited neither analgesic nor antiinflammatory activity. All compds. introduced intracutaneously in the form of 2% solns. produced pronounced local irritant action. Most of the 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides showed local anesthetic activity according to the conduction anesthesia test, but had no effect in the surface anesthesia test.

ACCESSION NUMBER: 2002:822385 HCAPLUS
DOCUMENT NUMBER: 139:95218
TITLE: Synthesis and pharmacological activity of 1,6-bisaryl-2,5-bis(aminomethyl)-1,6-hexanedione dihydrochlorides. Synthesis of 1,8-bisaryl-2,7-bis(aminomethyl)-1,8-octanedione dihydrochlorides
AUTHOR(S): Agababyan, A. G.; Gevorgyan, G. A.; Sarkisyan, Dz. S.; Tumadzhyan, A. E.
CORPORATE SOURCE: Mndzhoyan Institute of Fine Organic Chemistry, National Academy of Sciences of Armenia, Yerevan, Armenia
SOURCE: Pharmaceutical Chemistry Journal (Translation of Khimiko-Farmatsevticheskii Zhurnal) (2002), 36(6), 292-294
CODEN: PCJOAU; ISSN: 0091-150X
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 560120-18-5P 560120-19-6P 560120-20-9P 560120-21-0P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)
RN 560120-18-5 HCAPLUS
CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis(4-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

RN 560120-19-6 HCAPLUS
CN 1,6-Hexanedione, 1,6-bis(4-ethoxyphenyl)-2,5-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-20-9 HCAPLUS
CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis(4-propoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-21-0 HCAPLUS
CN 1,6-Hexanedione, 1,6-bis(4-butoxyphenyl)-2,5-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 560120-29-8P 560120-30-1P 560120-31-2P
560120-32-3P 560120-33-4P 560120-34-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and
synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)
RN 560120-29-8 HCAPLUS
CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-30-1 HCAPLUS
CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis(4-methoxyphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-31-2 HCAPLUS
CN 1,8-Octanedione, 1,8-bis(4-ethoxyphenyl)-2,7-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-32-3 HCAPLUS
CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis(4-propoxyphenyl)-,

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

IT 560120-17-4P 560120-22-1P
RL: ADV (Adverse effect, including toxicity); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(synthesis and pharmacol. activity of aryl(aminomethyl)hexanediones and
synthesis of aryl(aminomethyl)octanediones in relation to local anesthetic activity and toxicity)
RN 560120-17-4 HCAPLUS
CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-22-1 HCAPLUS
CN 1,6-Hexanedione, 2,5-bis[(ethylamino)methyl]-1,6-bis[4-(pentyloxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L21 ANSWER 18 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-33-4 HCAPLUS
CN 1,8-Octanedione, 1,8-bis(4-butoxyphenyl)-2,7-bis[(ethylamino)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 560120-34-5 HCAPLUS
CN 1,8-Octanedione, 2,7-bis[(ethylamino)methyl]-1,8-bis[4-(pentyloxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Jul 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a new multi-step process for preparing (±)-trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine [(±)-I], an important intermediate in the preparation of the well-known antidepressants paroxetine and omiloxetine. The invention also relates to: (1) various novel intermediates formed in the new preparation of (±)-I, (2) methods for preparing these new intermediates, and (3) the use of either the new intermediates or derived (±)-I for preparing paroxetine or omiloxetine. The new method avoids a host of specific problems which occur in several existing methods of preparing (±)-I. In particular, 3 functional groups are simultaneously reduced, providing the desired trans stereochem. in I directly, and avoiding the need for further epimerization steps. For instance, Mannich reaction of p-fluoroacetophenone with PhCH2NHMe.HCl and paraformaldehyde gave 84% of novel intermediate II.HCl. Hydrogenolytic debenzylation of the latter (96%) and amidation of the resultant novel secondary amine with ClCOCH2CO2Me (88%) gave the new intermediate ester III. Base-catalyzed cyclization of III using MeONa in MeOH gave, depending upon conditions, pyridinone IV (82%) or a 1:1 mixture of IV and its double-bond isomer V (90%). Reduction of IV and/or V using, e.g., LiAlH4 in THF, gave (±)-I without contamination by epimers, in good (65%) yield.

ACCESSION NUMBER: 2002:521706 HCAPLUS
DOCUMENT NUMBER: 137:78863
TITLE: Novel process for preparing (±)-trans-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-methylpiperidine, an intermediate for paroxetine and omiloxetine.
INVENTOR(S): Foguet, Rafael; Ramentol, Jorge; Petschen, Ines; Sallares, Juan; Camps, Francesc X.; Raga, Manuel M.; Castello, Joseph M.; Armengol, Miguel P.; Fernandez-Cano, Diego
PATENT ASSIGNEE(S): Ferrer Internacional S.A., Spain
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053537	A1	20020711	WO 2001-EP49	20010104
WO 2002053537	C1	20020808		

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 19 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

W: AU, BR, CA, IL, JP, KR, MX, NO, NZ, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2433605	AA	20020711	CA 2001-2433605	20010104
EP 1347960	A1	20031001	EP 2001-901146	20010104
EP 1347960	B1	20041117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
BR 2001016721	A	20031223	BR 2001-16721	20010104
JP 2004520333	T2	20040708	JP 2002-554656	20010104
AT 282594	E	20041215	AT 2001-901146	20010104
PT 1347960	T	20050331	PT 2001-901146	20010104
ES 2232588	T3	20050601	ES 2001-1901146	20010104
NZ 526874	A	20050729	NZ 2001-526874	20010104
TW 593279	B	20040621	TW 2001-90104450	20010227
NO 2003003049	A	20030818	NO 2003-3049	20030703
ZA 2003005207	A	20040705	ZA 2003-5207	20030704
US 2004215020	A1	20041028	US 2003-250519	20030915
US 6881845	B2	20050419		
PRIORITY APPLN. INFO.:			EP 2001-901146 A	20010104
			WO 2001-EP49 W	20010104

OTHER SOURCE(S): CASREACT 137:78863; MARPAT 137:78863
IT 440673-07-4P, 1-(p-Fluorophenyl)-3-(methylamino)propan-1-one hydrochloride 440673-11-0P, 1-(p-Fluorophenyl)-3-(methylamino)propan-1-one
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process intermediate; improved preparation of (fluorophenyl)(hydroxymethyl) methylpiperidine as intermediate for paroxetine and omiloxetine)
RN 440673-07-4 HCAPLUS
CN 1-Propanone, 1-(4-fluorophenyl)-3-(methylamino)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 440673-11-0 HCAPLUS
CN 1-Propanone, 1-(4-fluorophenyl)-3-(methylamino)- (9CI) (CA INDEX NAME)

L21 ANSWER 20 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Apr 2002
AB A general scheme was developed for the cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate, based on the successive oxidation of the allylic triad of carbon atoms in the piperidine ring. In the case of 4-aryltetrahydropyridines 2-oxotetrahydropyridines are formed initially. 3,4-Dihydroxypiperidin-2-ones and finally 1-aminoalkan-3-ones are then formed. The oxidation of 4-methyl-substituted tetrahydropyridines to the analogous 1-aminoalkanones begins differently - with 3,4-dihydroxylation followed by lactamization of the piperidinediols.

ACCESSION NUMBER: 2002:283018 HCAPLUS
DOCUMENT NUMBER: 137:78622
TITLE: Oxidative reactions of azines. 9. Cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate
AUTHOR(S): Soldatenkov, A. T.; Temesgen, A. V.; Bekro, I. A.
CORPORATE SOURCE: Russian Peoples Friendship University, Moscow, 117193, Russia
SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(10), 1216-1222
CODEN: CHCCAL; ISSN: 0009-3122
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:78622
IT 27152-62-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(cascade and stage oxidation of 1,4-disubstituted 1,2,3,6-tetrahydropyridines by potassium permanganate)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 21 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Jan 2002
GI



I

AB The title compds. [I; E = a bond; C(R4)2; R1, R2 = H, alkyl; R3 = H, alkyl, cycloalkyl, etc.; R4, R5 = H, alkyl], for inhibiting MRP1 in a mammal (no data), were prepared E.g., a multi-step synthesis of I [E = CH2;
R1-R2 = H; R3 = Ph; R5 = H] was given.
ACCESSION NUMBER: 2002:10444 HCAPLUS
DOCUMENT NUMBER: 136:69745
TITLE: Preparation of quinoline-2,4-diones for inhibiting MRP1
INVENTOR(S): Bonjouklian, Rosanne; York, Jeremy Schulenburg
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000624	A2	20020103	WO 2001-US10849	20010612
WO 2002000624	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413579	AA	20020103	CA 2001-2413579	20010612
AU 2001068040	A5	20020108	AU 2001-68040	20010612
EP 1296953	A2	20030402	EP 2001-945932	20010612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003232854	A1	20031218	US 2002-297275	20021204
US 6686376	B2	20040203		
PRIORITY APPLN. INFO.:			US 2000-213380P	P 20000623

L21 ANSWER 21 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
WO 2001-US10849 W 20010612

OTHER SOURCE(S): MARPAT 136:69745
IT 384850-10-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoline-2,4-diones for inhibiting MRP1)
RN 384850-10-6 HCAPLUS
CN 2-Pentenoic acid, 5-(2-chloro-6-fluorophenyl)-3-(methylamino)-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



L21 ANSWER 22 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 10 Aug 2001
GI



I

AB The title compds. I [R1 and R2 are each hydrogen, nitro, cyano, halogeno, C1-6 alkyl, C1-6 alkylsulfonyl, or the like; R3 is nitro, cyano, halogeno,
C1-6 alkyl, or the like; n is 0, 1 or 2; R4 and R5 are each hydrogen, C1-6
alkyl, C1-6 alkoxy, or the like, or alternatively they may be united to form an alkylene chain, a heterocyclic group, or the like; X is oxygen or sulfur; and Z is formyl, di(C1-6 alkoxy)methyl, Ph, a heterocyclic group, or the like] are prepared
3-(Azetidin-1-yl)-2-[2-methyl-3-(3-methylisoxazol-5-yl)-4-(methylsulfonyl)phenyl]-3-oxopropanenitrile at 250 g/ha gave 80% to 89% control of Abutilon avicennae.
ACCESSION NUMBER: 2001:581835 HCAPLUS
DOCUMENT NUMBER: 135:152794
TITLE: Preparation of substituted cyanoacetamide derivatives as herbicides
INVENTOR(S): Yamanaka, Hiroyuki; Kajita, Satoshi; Tanaka, Katsunori; Koguchi, Masami; Yamada, Shigeo; Takahashi, Akihiro
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd, Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056979	A1	20010809	WO 2001-JP603	20010130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2000-27226	A 20000131
			JP 2000-304838	A 20001004

L21 ANSWER 22 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 135:152794
IT 353236-70-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted cyanoacetamide derivs. as herbicides)
RN 353236-70-1 HCAPLUS
CN Benzenepropanamide, α-cyano-N,2-dimethyl-3-(3-methyl-5-isoxazolyl)-4-(methylsulfonyl)-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 23 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Jul 2001
GI



I

AB The invention relates to piperidine-substituted α- or β-amino acids [(I); R = (un)saturated (un)substituted heterocycle; R1 = Ph, naphthyl, (un)substituted heterocycle; R2 = H, alkyl; A, A1 = H; when one of A or A1 = H, the other = NH2, 1,4'-bipiperidyl, alkylamino, N(R3)(Z-R4)(forming (substituted) α- or β-amino acid); R3 = H, alkyl; Z = C(O), SO2; R4 = alkoxy, amino, (di)alkylamino, substituted heterocycle] their tautomers, diastereomers, enantiomers, mixts., and to their salts, in particular, their physiol. compatible salts with inorg. or organic acids or bases, which comprise valuable pharmacol. properties, in particular, CGRP-antagonistic properties. The invention also relates to medicaments containing these compds., to their use and to methods for the production thereof; formulations were given. Preparation of fragments CO2HC(R2)AC(O)R1, and A or A1 substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2-[(1,1-dimethylethoxy carbonyl)methylamino]-4-oxo-butanoic acid was reacted with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R1 = 4-amino-3,5-dibromophenyl; R2 = H; A = (1,1-dimethylethoxy carbonyl)methylamino; A1 = H). In in vitro tests using SK-N-MC cells as tests of human CGRP-receptor binding affinity, I had IC50 ≤10000 nM, and acted as CGRP antagonists at dosages between 10-11 - 10-5 M.

ACCESSION NUMBER: 2001:507689 HCAPLUS
DOCUMENT NUMBER: 135:92860
TITLE: Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders
INVENTOR(S): Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander; Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049676	A1	20010712	WO 2000-EP13236	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19963868	A1	20010712	DE 1999-19963868	19991230
CA 2395541	AA	20010712	CA 2000-2395541	20001222
BR 2000017063	A	20021022	BR 2000-17063	20001222
EP 1252153	A1	20021030	EP 2000-991806	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200300002	A2	20030528	HU 2003-2	20001222
JP 2003519222	T2	20030617	JP 2001-550216	20001222
EE 200200369	A	20031015	EE 2002-369	20001222
AU 783275	B2	20051006	AU 2001-35379	20001222
NZ 519939	A	20060831	NZ 2000-519939	20001222
BG 106848	A	20021229	BG 2002-106848	20020620
ZA 2002005181	A	20030930	ZA 2002-5181	20020627
NO 2002003161	A	20020628	NO 2002-3161	20020628
US 2003212057	A1	20031113	US 2002-169009	20021107
US 6949541	B2	20050927		
HK 1054026	A1	20050916	HK 2003-106237	20030901

PRIORITY APPLN. INFO.: DE 1999-19963868 A 19991230
WO 2000-EP13236 W 20001222

OTHER SOURCE(S): MARPAT 135:92860
IT 349534-94-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders)
RN 349534-94-7 HCAPLUS
CN Piperidine, 1-[4-(4-amino-3,5-dibromophenyl)-2-(methylamino)-1,4-dioxobutyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L21 ANSWER 23 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 26 Jan 2001
GI



I

AB Title compds. [I; R = H, OH, bond; R1, R2 = H, alkyl, aryl, aralkyl; R3 = H, OH, NH2, halo, alkyl, alkenyl, aryl, aralkyl, OR7, etc.; R4-R6 = H, OH, cyano, halo, alkyl, aryl, heterocyclyl; aralkyl, heterocyclylalkyl, OR7, SR7, etc.; R7 = alkyl, aryl, aralkyl; R12 = H, alkyl, cycloalkyl, aryl, aralkyl], were prepared Thus, 1-(3-methoxyphenyl)-3-phenylpropan-1-one (preparation given) was heated with paraformaldehyde iminium salt and dimethylamine hydrochloride in MeCN at 60° to give 83% 2-benzyl-3-dimethylamino-1-(3-methoxyphenyl)propan-1-one hydrochloride. Tested I at 10 mg/kg i.v. in mice gave 62-100% inhibition of phenylquinone-induced writhing.

ACCESSION NUMBER: 2001:63953 HCAPLUS
DOCUMENT NUMBER: 134:131314
TITLE: Preparation of 3-amino-2-benzyl-1-phenylpropanes as drugs.
INVENTOR(S): Sattlegger, Michael; Buschmann, Helmut; Koegel, Babette-Yvonne
PATENT ASSIGNEE(S): Grunenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005743	A1	20010125	WO 2000-EP5820	20000623
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19933421	A1	20010125	DE 1999-19933421	19990716
CA 2378723	AA	20010125	CA 2000-2378723	20000623
EP 1196373	A1	20020417	EP 2000-943873	20000623

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 2000012622	A	20020611	BR 2000-12622		20000623
HU 200201797	A2	20021228	HU 2002-1797		20000623
JP 2003505358	T2	20030212	JP 2001-511404		20000623
NZ 517164	A	20040227	NZ 2000-517164		20000623
AU 778632	B2	20041216	AU 2000-58189		20000623
NO 2002000212	A	20020115	NO 2002-212		20020115
US 2002161262	A1	20021031	US 2002-46567		20020116
US 6653508	B2	20031125			
ZA 2002001276	A	20030514	ZA 2002-1276		20020214
PRIORITY APPLN. INFO.:			DE 1999-19933421	A	19990716
			WO 2000-EP5820	W	20000623

OTHER SOURCE(S): MARPAT 134:131314
IT 321749-42-2P 321749-43-3P 321749-48-8P
321749-49-9P 321749-50-2P 321749-51-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-amino-2-benzyl-1-phenylpropanes as drugs)
RN 321749-42-2 HCAPLUS
CN 1-Propanone, 1-(3-methoxyphenyl)-2-[(methylamino)methyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 321749-43-3 HCAPLUS
CN 1-Propanone, 1-(3-methoxyphenyl)-2-[(methylamino)methyl]-3-(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321749-48-8 HCAPLUS
CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-methoxyphenyl)-2-

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 321749-49-9 HCAPLUS
CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-methoxyphenyl)-2-[(methylamino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321749-50-2 HCAPLUS
CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-hydroxyphenyl)-2-[(methylamino)methyl]- (9CI) (CA INDEX NAME)



RN 321749-51-3 HCAPLUS
CN 1-Propanone, 3-(3-fluorophenyl)-1-(3-hydroxyphenyl)-2-[(methylamino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 24 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L21 ANSWER 25 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Sep 2000
AB Fluoxetine-HCl was prepared by seven different synthetic routes, all previously reported. The major impurities in each route were identified by GC/MS, HPLC/MS, and gradient HPLC anal. Impurities were classified as being derived from impurities in 4-chlorobenzotrifluoride, those arising during the SNAr reaction of this compound and 3-methylamino-1-phenylpropanol, and those arising during the synthesis of this alc. Fifteen impurities belonging to the latter two categories were identified, and their structures were confirmed by synthesis of authentic material for most of the compds. It was found that a variety of anal. tools was needed for complete characterization of the impurity profile of fluoxetine HCl and that purification of the intermediate and recrystn. of the drug itself are highly effective in minimizing the levels of the impurities.
ACCESSION NUMBER: 2000:683252 HCAPLUS
DOCUMENT NUMBER: 134:21369
TITLE: Identification and Comparison of Impurities in Fluoxetine Hydrochloride Synthesized by Seven Different Routes
AUTHOR(S): Wirth, David D.; Miller, Marybeth S.; Boini, Sathish K.; Koenig, Thomas M.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Co., Lafayette, IN, 47909-9201, USA
SOURCE: Organic Process Research & Development (2000), 4(6), 513-519
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 27152-62-1P
RL: BYP (Byproduct); PREP (Preparation)
(impurities in fluoxetine hydrochloride synthesized by seven different routes)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L21 ANSWER 26 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 14 Aug 2000
AB 4-Morpholinocoumarin was obtained in the reaction of 4-(2-hydroxythiobenzoyl)morpholine with Et bromoacetate in the presence of PPh3 and NEt3. Analogous reactions of 3-keto thioamides with Et bromoacetate and Et 2-bromopropionate, carried out in THF or acetone, yielded cyclic derivs. of N-subatituted 2-acylmethylidene-1,3-thiazolidin-4-ones. In the reaction with Et 3-bromopropionate only S-alkylation of the thioamide was observed The reaction of the indandione-derived thioamides with Et bromoacetate in acetone gave the condensation products of 2-acylmethylidene-1,3-thiazolidin-4-ones with acetone. 2-Acylmethylidene-1,3-thiazolidin-4-ones condensed with benzaldehyde to give the 5-benzylidene derivs.
ACCESSION NUMBER: 2000:558201 HCAPLUS
DOCUMENT NUMBER: 133:281742
TITLE: Reactions of secondary β-ketothioamides with ethyl bromoacetate and ethyl 2-bromopropionate. The synthesis of N-substituted 2-acylmethylidene-1,3-thiazolidin-4-ones
AUTHOR(S): Jagodzinski, T. S.; Wesolowska, A.; Sosnicki, J. G.
CORPORATE SOURCE: Department of Organic Chemistry, Technical University of Szczecin, Szczecin, 71-065, Pol.
SOURCE: Polish Journal of Chemistry (2000), 74(8), 1101-1114
CODEN: PJCHDQ; ISSN: 0137-5083
PUBLISHER: Polish Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:281742
IT 56617-74-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant for preparation of acylmethylidenethiazolidinones)
RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 27 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 Aug 2000
AB The carboxylic groups of horseradish peroxidase were modified by 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate by the Koshland method. The catalytic properties of the native and modified peroxidase were studied in the presence of N-ethylamide of o-sulfobenzoylacetic acid (EASBA) at pH 5.0-7.5. In the oxidation of o-dianisidine, EASBA is a competitive inhibitor of the carbodiimide-modified peroxidase, and it increases both Km and Vm in the case of the native enzyme. These data show that at least one of the carboxylic groups modified with carbodiimide is located at the area of the peroxidase active site.
ACCESSION NUMBER: 2000:552386 HCAPLUS
DOCUMENT NUMBER: 133:292793
TITLE: Inhibition of horseradish peroxidase by N-ethylamide of o-sulfobenzoylacetic acid
AUTHOR(S): Rogozhin, V. V.; Kutuzova, G. D.; Ugarova, N. N.
CORPORATE SOURCE: Yakutsk State Agricultural Academy, Yakutsk, 677002, Russia
SOURCE: Russian Journal of Bioorganic Chemistry (Translation of Bioorganicheskaya Khimiya) (2000), 26(2), 138-141
CODEN: RJBCET; ISSN: 1068-1620
PUBLISHER: MAIK Nauka/Interperiodica
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 103383-39-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of horseradish peroxidase by N-ethylamide of sulfobenzoylacetic acid)
RN 103383-39-7 HCAPLUS
CN Benzenesulfonic acid, 3-[3-(ethylamino)-1,3-dioxopropyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 28 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Dec 1999
GI



AB Water is supplied to an exposed photosensitive material using a spray or an elastic porous substance impregnated with water, wherein the photosensitive material contains photosensitive Ag halide, a binder, anilide I (R1, R4 = H, substituent; A = OH, amino; X = CO, SO, SO2, PO; Y = divalent group; Z = nucleophilic group), and a compound forming a diffusible pigment by reaction with oxidized I. The method prevents dissoln. of the chems. of the material into H2O. The diagrams of the water supplying apps. are given.
ACCESSION NUMBER: 1999:814652 HCAPLUS
DOCUMENT NUMBER: 132:71429
TITLE: Image formation using heat development photosensitive material
INVENTOR(S): Taguchi, Keiichi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11352648	A2	19991224	JP 1998-172126	19980605
PRIORITY APPLN. INFO.:			JP 1998-172126	19980605

OTHER SOURCE(S): MARPAT 132:71429
IT 253178-14-2
RL: DEV (Device component use); USES (Uses)
(coupler; image formation using heat development photosensitive material)
RN 253178-14-2 HCAPLUS
CN Benzenepropanamide, α-[3-[[[4-(dodecyloxy)phenyl]sulfonyl]amino]phenoxy]-N-ethyl-4-[(methylsulfonyl)amino]-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 28 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L21 ANSWER 29 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Mar 1999
GI



AB Photocyclization of the heterocyclic 2,3-diones I (X = O, S, NH, NMe) with electron rich alkenes affords regio- and stereoselectively the [2+2] adducts II (R = OAc, Ph, OEt). From I (X = S), with benzophenone as photosensitizer, the Paterno-Buchi adduct III was also obtained. Similarly, with phenylethyne the didehydro derivs. of II (R = Ph) were formed in moderate to low yields and, in case of I (X = NH), an azepinone was the only product. Irradiation of I (X = NPh, 4-MeC6H4N] with EtOCH:CH2 gave the furo[3,2-c]pyrrolones IV (R = Ph, 4-MeC6H4) via an unexpected 1,2-benzoyl migration. Structural elucidation of all ring systems is based on x-ray anal.

ACCESSION NUMBER: 1999:176586 HCAPLUS
DOCUMENT NUMBER: 130:325096
TITLE: Reactions of cyclic oxalyl compounds. 41. Regio- and stereoselective photocycloadditions of heterocyclic 2,3-diones - evidence for an unexpected 1,2-aroyl migration
AUTHOR(S): Kollenz, G.; Terpetschnig, E.; Sterk, H.; Peters, K.; Peters, E.-M.
CORPORATE SOURCE: Institute for Organic Chemistry, Karl-Franzens University Graz, Graz, A-8010, Austria
SOURCE: Tetrahedron (1999), 55(10), 2973-2984
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal

L21 ANSWER 29 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
LANGUAGE: English
IT 223916-45-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(regio- and stereoselective photocycloaddns. of heterocycle diones and aroyl migration in photolysis of benzoylarylpyrroledione)
RN 223916-45-8 HCAPLUS
CN 2-Butenamide, 3-benzoyl-2,4-dihydroxy-N-methyl-4-(methylamino)-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 30 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Jun 1998
AB Asym. hydrogenation of PhCOCH2CONHMe under 200 psi of hydrogen pressure in the presence of a chiral BINAP-ruthenium(II) catalyst furnished (R)- or (S)-PhCH(OH)CH2CONHMe as the single enantiomer. The product can be used as an intermediate for chiral fluoxetine.

ACCESSION NUMBER: 1998:395523 HCAPLUS
DOCUMENT NUMBER: 129:135958
TITLE: The synthesis of a chiral fluoxetine intermediate by catalytic enantioselective hydrogenation of benzoylacetamide
AUTHOR(S): Huang, Hsiang-Ling; Liu, Lee Tai; Chen, Shyh-Fong; Ku, Hao
CORPORATE SOURCE: Development Center for Biotechnology, Taipei, Taiwan
SOURCE: Tetrahedron: Asymmetry (1998), 9(10), 1637-1640
CODEN: TASYE3; ISSN: 0957-4166
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:135958
IT 197852-01-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a chiral fluoxetine intermediate by catalytic enantioselective hydrogenation of benzoylacetamide)
RN 197852-01-0 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 31 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Jan 1998
AB Gradient HPLC and gas chromatog. were applied as screening methods for determination of impurities in fluoxetine HCl drug substances and formulated products from multiple sources. NMR spectroscopy was also used for identification of excipients and some residual solvents. Thirty potential impurities and excipients were investigated. Several impurities were observed in generic products using gradient HPLC that were not detected with isocratic pharmacopeial methods for fluoxetine HCl. Anal. of drug substance samples and capsule formulations from many different suppliers showed a wide variation in quality which, in many cases, would go undetected using isocratic methods. The quality of the innovator's product and some generic samples was high, but many generic samples contained high levels of impurities. A new impurity, N-benzyl fluoxetine, was observed in some generic samples at levels as high as 0.9%. The gradient HPLC method was also used for stability studies and established that generic capsules formulated with lactose were less stable under accelerated conditions than those formulated without lactose.

ACCESSION NUMBER: 1998:26204 HCAPLUS
DOCUMENT NUMBER: 128:132529
TITLE: Screening methods for impurities in multi-sourced fluoxetine hydrochloride drug substances and formulations
AUTHOR(S): Wirth, D. D.; Olsen, B. A.; Hallenbeck, D. K.; Lake, M. E.; Gregg, S. M.; Perry, F. M.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly Co., Lafayette, IN, 47902, USA
SOURCE: Chromatographia (1997), 46(9/10), 511-523
CODEN: CHRGB7; ISSN: 0009-5893
PUBLISHER: Friedrich Vieweg & Sohn Verlagsgesellschaft mbH
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 27152-62-1P
RL: ANT (Analyte); BYP (Byproduct); FMU (Formation, unclassified); ANST (Analytical study); FORM (Formation, nonpreparative); PREP (Preparation)
(screening methods for impurities in fluoxetine HCl drug substances and formulations)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 32 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 30 Oct 1997
AB Incubation of the fungus Mortierella isabellina NRRL 1757 with 3-oxo-3-phenylpropanamide, 3-oxobutanamide, and with some of their N-alkyl derivs. afford the corresponding (S)-3-hydroxyamides, usually in high chemical yields and enantiomeric excesses.
ACCESSION NUMBER: 1997:686378 HCAPLUS
DOCUMENT NUMBER: 127:330950
TITLE: Enantioselective reduction of β-keto amides by the fungus Mortierella isabellina
AUTHOR(S): Quiros, Margarita; Rebolledo, Francisca; Liz, Ramon; Gotor, Vicente
CORPORATE SOURCE: Laboratorio de Quimica Bioorganica, Facultad de Quimica, Universidad de Oviedo, Oviedo, 33071, Spain
SOURCE: Tetrahedron: Asymmetry (1997), 8(18), 3035-3038
CODEN: TASYE3; ISSN: 0957-4166
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 127:330950
IT 197852-01-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective reduction of β-keto amides by the fungus Mortierella isabellina)
RN 197852-01-0 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 33 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 30 Oct 1997
AB A thin layer chromatog. method to examine the related substances (ω-methylaminophenylpropanone, N-methyl-3-hydroxy-3-phenylpropane, etc) from the synthetic process of fluoxetine hydrochloride was established.
ACCESSION NUMBER: 1997:684913 HCAPLUS
DOCUMENT NUMBER: 127:283475
TITLE: TLC examination of related substances in fluoxetine hydrochloride
AUTHOR(S): Gao, Damin; Wang, Aimin
CORPORATE SOURCE: Shanghai Institute of Pharmaceutical Industry, Shanghai, 200437, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (1997), 28(4), 175-177
CODEN: ZYGZEA; ISSN: 1001-8255
PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
IT 27152-62-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of fluoxetine impurities by TLC)
RN 27152-62-1 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 34 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Jun 1997
AB The addition reaction of ω-bromoacetophenone to aldimines R1CH:NR2 (R1 = Ph, 2-ClC6H4, 4-O2NC6H4, 4-MeC6H4, 4-MeOC6H4; R2 = Ph, 2-MeC6H4, Me, n-Bu) by indium metal in THF-H2O gave β-amino ketones R1CH(NHR2)CH2COPh.
ACCESSION NUMBER: 1997:366757 HCAPLUS
DOCUMENT NUMBER: 127:81201
TITLE: Indium-mediated addition of α-bromo ketone to aldimines
AUTHOR(S): Sun, Pei Pei; Zhang, Yong Min
CORPORATE SOURCE: Department of Chemistry, Hangzhou University, Hangzhou, 310028, Peop. Rep. China
SOURCE: Chinese Chemical Letters (1997), 8(4), 267-268
CODEN: CCLEE7
PUBLISHER: Chinese Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 24686-91-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(indium-mediated addition of α-bromoacetophenone to aldimines)
RN 24686-91-7 HCAPLUS
CN 1-Propanone, 3-(methylamino)-1,3-diphenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 25 Sep 1996
GI



AB Drugs containing a β-oxo-β-benzenepropane-thioamide derivative represented by general formula (I; R1 and R2 represent each independently C1-6 alkyl, or R1 and R2 bind to each other to form C2-5 alkylene; R3 and R4 represent each independently hydrogen, halogeno, C1-6 alkyl, C1-6 alkoxy, trifluoromethyl, cyano, nitro, C2-6 dialkylamino or imidazolyl, optionally having one or more substituents selected from C1-6 alkyl, C1-6 alkoxy and halogeno) as the active ingredient are useful in the treatment and prevention of kidney diseases, diseases caused by the proliferation of smooth muscle fibers and heart diseases.
ACCESSION NUMBER: 1996:569661 HCAPLUS
DOCUMENT NUMBER: 125:212684
TITLE: Cardiovascular and renal agents containing β-oxo-β-benzenepropanethioamide derivatives
INVENTOR(S): Bessho, Hideki; Abe, Youichi; Tamaki, Toshiaki; Kimura, Shoji; Aki, Yasuharu; Mitsuka, Masayoshi; Nagae, Mieko; Seino, Asami; Narimatsu, Akihiro; Abe, Yuji
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622086	A1	19960725	WO 1996-JP46	19960116
W: CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 07244393	A2	19950919	JP 1995-4949	19950117
PRIORITY APPLN. INFO.:			JP 1995-4747 A	19950117
			JP 1995-4748 A	19950117
			JP 1995-4949 A	19950117
			JP 1994-3088 A	19940117

OTHER SOURCE(S): MARPAT 125:212684
IT 56617-74-4D, derivs. 150515-00-7 150515-01-8 150515-03-0 150515-04-1 150515-05-2 150515-06-3 150515-07-4 150515-08-5 150515-09-6 150515-10-9 150515-11-0

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

150515-12-1 150515-13-2 150515-14-3
150515-15-4 150515-16-5 150515-17-6
150515-19-8 150515-59-6 150515-60-9
150515-62-1 181237-78-5 181237-79-6
181237-80-9 181237-81-0 181237-82-1
181237-83-2 181237-84-3 181237-85-4
181237-86-5 181237-87-6 181237-88-7
181237-89-8 181237-90-1 181237-91-2
181237-92-3 181237-93-4 181237-94-5
181237-95-6 181237-96-7 181237-97-8
181237-98-9 181237-99-0 181238-00-6
181238-01-7 181238-02-8 181238-03-9
181238-04-0 181238-05-1 181238-06-2
181238-07-3 181238-08-4 181238-09-5
181238-10-8 181238-11-9 181238-12-0
181238-13-1 181238-14-2 181238-15-3
181238-16-4 181238-17-5 181238-18-6
181238-19-7 181238-20-0 181238-21-1
181238-22-2 181238-23-3 181238-24-4
181238-25-5 181238-26-6 181238-27-7
181238-28-8 181238-29-9 181238-30-2
181238-31-3 181238-32-4 181238-33-5
181238-34-6 181238-35-7 181238-36-8
181238-37-9 181238-38-0 181238-39-1
181238-40-4 181238-41-5 181238-42-6
181238-43-7 181238-44-8 181238-45-9
181238-46-0 181238-47-1 181238-48-2
181238-49-3 181238-50-6 181238-51-7
181238-52-8 181238-53-9 181238-54-0
181238-55-1 181238-56-2 181238-57-3
181238-58-4 181238-59-5 181238-60-8
181239-39-4 181239-40-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiovascular and renal agents contg. β-oxo-β-benzenepropanethioamide derivs.)

RN 56617-74-4 HCAPLUS
CN Benzenepropanethioamide, N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-00-7 HCAPLUS
CN Benzenepropanethioamide, N,α,α,4-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-01-8 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-03-0 HCAPLUS
CN Benzenepropanethioamide, 4-fluoro-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-04-1 HCAPLUS
CN Benzenepropanethioamide, 4-bromo-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-05-2 HCAPLUS
CN Benzenepropanethioamide, 4-cyano-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-06-3 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-07-4 HCAPLUS
CN Benzenepropanethioamide, 3-fluoro-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-08-5 HCAPLUS
CN Benzenepropanethioamide, 3-chloro-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-09-6 HCAPLUS
CN Benzenepropanethioamide, N,α,α,3-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-10-9 HCAPLUS
CN Benzenepropanethioamide, 3-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-11-0 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-12-1 HCAPLUS
CN Benzenepropanethioamide, 3-(2-iodo-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-13-2 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-3-(2-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-14-3 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-4-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-15-4 HCAPLUS
CN Benzenepropanethioamide, 4-ethoxy-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-16-5 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-60-9 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-N,α,α-trimethyl-3-(2-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-62-1 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-3-(2-methoxy-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-78-5 HCAPLUS
CN Benzenepropanethioamide, N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-79-6 HCAPLUS
CN Benzenepropanethioamide, 4-fluoro-N,α-dimethyl-β-oxo- (9CI)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 150515-17-6 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-2-[2-(1-methylethyl)-1H-imidazol-1-yl]-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-19-8 HCAPLUS
CN Benzenepropanethioamide, α,α-diethyl-4-(1H-imidazol-1-yl)-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 150515-59-6 HCAPLUS
CN Benzenepropanethioamide, 3-(2-iodo-1H-imidazol-1-yl)-4-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



RN 181237-80-9 HCAPLUS
CN Benzenepropanethioamide, 4-methoxy-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-81-0 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-82-1 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-83-2 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-84-3 HCAPLUS
CN Benzenepropanethioamide, 3-chloro-4-(1H-imidazol-1-yl)-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-85-4 HCAPLUS
CN Benzenepropanethioamide, α-ethyl-4-(1H-imidazol-1-yl)-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181237-86-5 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N-methyl-α-(1-methylethyl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-87-6 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N-methyl-β-oxo-α-propyl- (9CI) (CA INDEX NAME)



RN 181237-88-7 HCAPLUS
CN Benzenepropanethioamide, α-hexyl-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181237-89-8 HCAPLUS
CN Benzenepropanethioamide, 4-chloro-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-90-1 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-β-oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 181237-91-2 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-4-(2-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-92-3 HCAPLUS
CN Benzenepropanethioamide, 4-(2-ethyl-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-93-4 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-4-[2-(1-methylethyl)-1H-imidazol-1-yl]-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-94-5 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-β-oxo-4-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 181237-95-6 HCAPLUS
CN Benzenepropanethioamide, 4-(2-iodo-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-96-7 HCAPLUS
CN Benzenepropanethioamide, 4-(2-methoxy-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-97-8 HCAPLUS
CN Benzenepropanethioamide, 4-(2-chloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181237-98-9 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-4-(4-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181237-99-0 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-4-(5-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-00-6 HCAPLUS
CN Benzenepropanethioamide, 4-(4,5-dichloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-01-7 HCAPLUS
CN Benzenepropanethioamide, 3-fluoro-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-02-8 HCAPLUS
CN Benzenepropanethioamide, 3-chloro-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-03-9 HCAPLUS
CN Benzenepropanethioamide, 3-bromo-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-04-0 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-3-iodo-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-05-1 HCAPLUS
CN Benzenepropanethioamide, 3-cyano-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-06-2 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α,3-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-07-3 HCAPLUS
CN Benzenepropanethioamide, 3-ethyl-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-08-4 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-3-(1-methylethyl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-09-5 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propyl- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-10-8 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-3-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-11-9 HCAPLUS
CN Benzenepropanethioamide, 3-ethoxy-4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-12-0 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-3-(1-methylethoxy)-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-13-1 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propoxy- (9CI) (CA INDEX NAME)



RN 181238-14-2 HCAPLUS
CN Benzenepropanethioamide, 4-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 181238-15-3 HCAPLUS
CN Benzenepropanethioamide, 3-(2-ethyl-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-16-4 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-3-[2-(1-methylethyl)-1H-imidazol-1-yl]-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-17-5 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-β-oxo-3-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 181238-18-6 HCAPLUS
CN Benzenepropanethioamide, 3-(2-methoxy-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-19-7 HCAPLUS
CN Benzenepropanethioamide, 3-(2-chloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-20-0 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-3-(4-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-21-1 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-3-(5-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-22-2 HCAPLUS
CN Benzenepropanethioamide, 3-(4,5-dichloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-23-3 HCAPLUS
CN Benzenepropanethioamide, 4-fluoro-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-24-4 HCAPLUS
CN Benzenepropanethioamide, 4-chloro-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-25-5 HCAPLUS
CN Benzenepropanethioamide, 4-bromo-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-26-6 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-4-iodo-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-27-7 HCAPLUS
CN Benzenepropanethioamide, 4-cyano-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-28-8 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α,4-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-29-9 HCAPLUS
CN Benzenepropanethioamide, 4-ethyl-3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-30-2 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-4-(1-methylethyl)-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-31-3 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-4-propyl- (9CI) (CA INDEX NAME)



RN 181238-32-4 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-4-(1-methylethoxy)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-33-5 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-4-propoxy- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-34-6 HCAPLUS
CN Benzenepropanethioamide, 3-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 181238-35-7 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-2-(2-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-36-8 HCAPLUS
CN Benzenepropanethioamide, 2-(2-ethyl-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-37-9 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-β-oxo-2-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 181238-38-0 HCAPLUS
CN Benzenepropanethioamide, 2-(2-iodo-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-39-1 HCAPLUS
CN Benzenepropanethioamide, 2-(2-methoxy-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-40-4 HCAPLUS
CN Benzenepropanethioamide, 2-(2-chloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-41-5 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-2-(4-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-42-6 HCAPLUS
CN Benzenepropanethioamide, N,α,α-trimethyl-2-(5-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-43-7 HCAPLUS
CN Benzenepropanethioamide, 2-(4,5-dichloro-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-48-2 HCAPLUS
CN Benzenepropanethioamide, 3-cyano-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-49-3 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α,3-tetramethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-50-6 HCAPLUS
CN Benzenepropanethioamide, 3-ethyl-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-51-7 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-3-(1-methylethyl)-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 181238-44-8 HCAPLUS
CN Benzenepropanethioamide, 3-fluoro-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-45-9 HCAPLUS
CN Benzenepropanethioamide, 3-chloro-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-46-0 HCAPLUS
CN Benzenepropanethioamide, 3-bromo-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-47-1 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-3-iodo-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-52-8 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propyl- (9CI) (CA INDEX NAME)



RN 181238-53-9 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-3-methoxy-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-54-0 HCAPLUS
CN Benzenepropanethioamide, 3-ethoxy-2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-55-1 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-(1-methylethoxy)-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-56-2 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-propoxy- (9CI) (CA INDEX NAME)



RN 181238-57-3 HCAPLUS
CN Benzenepropanethioamide, 2-(1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 181238-58-4 HCAPLUS
CN Benzenepropanethioamide, α,α-diethyl-3-fluoro-4-(1H-imidazol-1-yl)-N-methyl-β-oxo- (9CI) (CA INDEX NAME)

L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 181238-59-5 HCAPLUS
CN Benzenepropanethioamide, α,α-dihexyl-4-(1H-imidazol-1-yl)-N-methyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181238-60-8 HCAPLUS
CN Benzenepropanethioamide, α-hexyl-4-(1H-imidazol-1-yl)-N,α-dimethyl-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 35 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 181239-39-4 HCAPLUS
CN Benzenepropanethioamide, 4-ethyl-3-(2-iodo-1H-imidazol-1-yl)-N,α,α-trimethyl-β-oxo- (9CI) (CA INDEX NAME)



RN 181239-40-7 HCAPLUS
CN Benzenepropanethioamide, 4-ethyl-N,α,α-trimethyl-3-(2-methyl-1H-imidazol-1-yl)-β-oxo- (9CI) (CA INDEX NAME)



L21 ANSWER 36 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 Sep 1996
AB The relative absorption coeffs. Arel = A(λ1)/A(λ2) at various fixed wavelengths used in the UV detection of organic compds. are superior in information content to chromatog. retention indexes of reversed-phase HPLC. To choose standard wavelengths, these coeffs. may be recommended for inclusion in data bases of anal. parameters designed for the identification of unknown compds. Also, Arel is useful for revealing the nature of chromophores in organic mols., as well as for the group identification of compds. from different groups of structural analogs.
ACCESSION NUMBER: 1996:535941 HCAPLUS
DOCUMENT NUMBER: 125:291931
TITLE: Relative absorption at different wavelengths as a complementary UV-spectroscopic parameter for the identification of organic compounds by reversed-phase high-performance liquid chromatography
AUTHOR(S): Zenkevich, I. G.; Kosman, V. M.
CORPORATE SOURCE: St. Petersburg Inst. Chem. Pharmacol., St. Petersburg, 197376, Russia
SOURCE: Journal of Analytical Chemistry (Translation of Zhurnal Analiticheskoi Khimii) (1996), 51(8), 802-806
CODEN: JACTE2; ISSN: 1061-9348
PUBLISHER: MAIK Nauka/Interperiodica
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 182880-27-9
RL: ANT (Analyte); ANST (Analytical study)
(organic compds. identification by reversed-phase HPLC using relative UV absorption coeffs.)
RN 182880-27-9 HCAPLUS
CN 1-Butanone, 3-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L21 ANSWER 37 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 10 Aug 1996
GI



I II

III

AB After deprotonation with LDA, 2-acyl-3-phenyl-1-menthopyrazoles I (R1 = Me, Et, CHMe2, Ph, PhCH2) were diastereomerically α-acylated to give N-(3-phenyl-1-menthopyrazolyl) β-keto amides II (R2 = Ph, Et, Me, CHMe2, CMe3, 4-MeC6H4). The subsequent amides were converted into the corresponding N-alkyl amides III (X = NHMe, NHCH2Ph, pyrrolidino) retaining their enantiomeric enrichment on the α-position. These are the first examples of enolizable β-keto acid derivs. having only one chiral center at the α-position. These chiral β-keto amides were surprisingly stable in dry benzene and their optical asymmetries were almost retained for two weeks at room temperature without any epimerization.

ACCESSION NUMBER: 1996:474764 HCAPLUS
DOCUMENT NUMBER: 125:247327
TITLE: Enantiomerically enriched preparation of enolizable β-keto amides. Diastereoselective α-acylation and subsequent aminolysis of 2-acyl-3-phenyl-1-menthopyrazoles
AUTHOR(S): Kashima, Choji; Fukuchi, Iwao; Takahashi, Katsumi; Hosomi, Akira
CORPORATE SOURCE: Dep. Chem., Univ. Tsukuba, ibaraki, 305, Japan
SOURCE: Tetrahedron (1996), 52(31), 10335-10346
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 181574-65-2P 181574-66-3P 181574-67-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of β-keto amides via stereoselective acylation and aminolysis of acylphenylmenthopyrazoles)

L21 ANSWER 37 OF 137 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 181574-65-2 HCAPLUS
CN Benzenepropanamide, N,α-dimethyl-β-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 181574-66-3 HCAPLUS
CN Benzenepropanamide, α-ethyl-N-methyl-β-oxo-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 181574-67-4 HCAPLUS
CN Benzenepropanamide, N-methyl-β-oxo-α-(phenylmethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).